I'm LongbridgeAI, I can summarize articles.Eton Pharmaceuticals has licensed U.S. rights to Auson’s late-stage ASN-001, a timolol topical gel for infantile hemangiomas. This deal expands Eton's franchise beyond HEMANGEOL. Phase II/III trials showed significant efficacy. An NDA is targeted for submission in the second half of 2027, with a potential U.S. launch planned for 2028. Eton estimates 20,000 to 30,000 annual candidates, positioning ASN-001 as a key revenue driver.
- Eton Pharmaceuticals licensed U.S. rights to Auson’s late-stage ASN-001, a timolol topical gel for proliferating superficial infantile hemangiomas. * Deal expands Eton’s infantile hemangioma franchise beyond HEMANGEOL, targeting moderate cases now often treated off-label with ophthalmic timolol. * Phase II/III trial (168 patients) showed 24-week elimination or near-elimination rates of 56% (BID) and 42% (TID) vs 15% placebo. * NDA submission targeted for 2H 2027 following a bioavailability bridging study; potential U.S. launch planned for 2028. * Eton estimates 20,000 to 30,000 patients a year could be candidates, positioning ASN-001 as a potential top revenue driver. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eton Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608050650PRIMZONEFULLFEED9803599) on August 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)